Nafamostat, Drugs Monitor

(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate

July 7, 2020

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series https://doi.org/10.1186/s13054-020-03078-z This is the first report on nafamostat mesylate treatment in combination with favipiravir against Covid-19. No interruption of antiviral treatment occurred due to… Continue reading "(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate"

(12 May 2020) Nafamostat- almost 600-fold more potent than remdesivir in Calu-3 cells

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate https://doi.org/10.1101/2020.05.12.090035 Authors identified 24 FDA-approved drugs which exhibited substantial antiviral effect against SARS-CoV-2 in Vero cells. They developed… Continue reading

Tag: Nafamostat

(06 July 2020) Favipiravir – low mortality rate with combination treatment of favipiravir and nafamostat mesylate

(12 May 2020) Nafamostat- almost 600-fold more potent than remdesivir in Calu-3 cells